Publications by authors named "O Danielsson"
Article Synopsis
- Patients with biliary tract cancer involving the hepatic hilum often require major liver and bile duct resections, with this study analyzing outcomes for various subtypes, including perihilar cholangiocarcinoma (PHCC), gallbladder cancer (GBC), and intrahepatic cholangiocarcinoma (IHCC).
- A total of 108 patients were assessed for overall survival, recurrence-free survival, and complications, revealing that IHCC and GBC presented more aggressive characteristics compared to PHCC, impacting prognosis.
- The findings indicated that while the overall survival rates were similar across all cancer types (29 months for PHCC, 22 months for GBC, and 21 months for IHCC), IHCC patients experienced
Article Synopsis
- The study investigated multiple acyl-coenzyme A dehydrogenase deficiency (MADD), a metabolic disorder, in patients without identified genetic mutations to explore potential non-genetic causes.
- Researchers reviewed medical records from the last decade, focusing on symptoms and treatment responses of 9 patients diagnosed with late-onset MADD, finding that all had muscle weakness and elevated creatine kinase levels.
- Results indicated that sertraline may trigger an acquired form of MADD, and while riboflavin treatment was effective in all patients, stopping sertraline improved outcomes for those affected.
Objectives: To determine prevalence and clinical associations of anti-FHL1 autoantibodies in patients with idiopathic inflammatory myopathies (IIM), and to evaluate autoantibody levels over time.
Methods: Sera at the time of diagnosis from patients with IIM (n = 449), autoimmune disease controls (DC, n = 130), neuromuscular diseases (NMD, n = 16) and healthy controls (HC, n = 100) were analyzed for anti-FHL1 autoantibodies by Enzyme-Linked ImmunoSorbent Assay (ELISA). Patients with IIM FHL1+ and FHL1- were included in a longitudinal analysis.
Fatty liver disease (FLD) affects approximately 25% of global adult population. Metabolic-associated fatty liver disease (MAFLD) is a term used to emphasize components of metabolic syndrome in FLD. MAFLD does not exclude coexistence of other liver disease, but impact of coexisting MAFLD is unclear.
View Article and Find Full Text PDF